寨卡病毒包膜蛋白同源 prime-boost 联合 poly(I:C) 诱导强效特异性体液和细胞免疫应答
本研究在小鼠中头对头比较基于寨卡病毒包膜糖蛋白(EZIKV)的不同疫苗候选(DNA、重组蛋白)、佐剂(poly(I:C)、CpG ODN 1826)及免疫策略(同源、异源)诱导的免疫应答。结果显示 poly(I:C) 佐剂优于 CpG ODN,且同源 EZIKV 蛋白+poly(I:C) prime-boost 方案诱导的体液应答强于同源 DNA 或异源方案;同源和异源 prime-boost 方案诱导的 IFN-γ 分泌细胞和细胞因子产生 CD4+ T 细胞量最高。总体表明同源 EZIKV+poly(I:C) prime-boost 足以诱导比其他策略更稳健的特异性体液和细胞免疫应答。
要点
- poly(I:C) 佐剂诱导的抗体和细胞免疫应答优于 CpG ODN 1826。
- 同源 EZIKV 蛋白+poly(I:C) prime-boost 的体液应答强于同源 DNA 或异源方案。
- 同源和异源 prime-boost 方案诱导最高水平的 IFN-γ 分泌细胞和细胞因子产生 CD4+ T 细胞。
核心结论
- 同源 EZIKV+poly(I:C) prime-boost 免疫足以诱导比其他同源 DNA 或异源策略更稳健的特异性抗 EZIKV 体液和细胞免疫应答。
研究设计与样本
- 在小鼠中头对头比较基于 EZIKV 的不同疫苗候选(DNA、重组蛋白)、佐剂(poly(I:C)、CpG ODN 1826)及免疫策略(同源、异源)诱导的免疫应答。
主要发现
- poly(I:C) 为优于 CpG ODN 的佐剂;poly(I:C) 辅助免疫在兩剂后抗体滴度达平台,而 CpG ODN 组需额外免疫剂量。
- poly(I:C) 给药诱导的 EZIKV 特异性细胞免疫应答高于 CpG ODN。
- 同源 prime-boost EZIKV 蛋白+poly(I:C) 方案诱导的体液应答比同源 DNA(pVAX-EZIKV)或异源方案(DNA/蛋白或蛋白/DNA)更稳健。
- 同源(EZIKV+poly(I:C))和异源(pVAX-EZIKV/EZIKV+poly(I:C))prime-boost 方案诱导最高水平的 IFN-γ 分泌细胞和细胞因子产生 CD4+ T 细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recent outbreaks of Zika virus (ZIKV) infection and the potential association with Guillain-Barré syndrome in adults and with congenital abnormalities have highlighted the urgency for an effective vaccine. The ZIKV Envelope glycoprotein (EZIKV) is the most abundant protein on the virus surface, and has been evaluated together with the pre-membrane protein (prM) of the viral coat as a vaccine candidate in clinical trials. In this study, we performed a head-to-head comparison of the immune response induced by different EZIKV-based vaccine candidates in mice. We compared different platforms (DNA, recombinant protein), adjuvants (poly (I:C), CpG ODN 1826) and immunization strategies (homologous, heterologous). The hierarchy of adjuvant potency showed that poly (I:C) was a superior adjuvant than CpG ODN. While poly (I:C) assisted immunization reached a plateau in antibody titers after two doses, the CpG ODN group required an extra immunization dose. Besides, the administration of poly (I:C) induced higher EZIKV-specific cellular immune responses than CpG ODN. We also show that immunization with homologous prime-boost EZIKV protein + poly (I:C) regimen induced a more robust humoral response than homologous DNA (pVAX-EZIKV) or heterologous regimens (DNA/protein or protein/DNA). A detailed analysis of cellular immune responses revealed that homologous (EZIKV + poly (I:C)) and heterologous (pVAX-EZIKV/EZIKV + poly (I:C)) prime-boost regimens induced the highest magnitude of IFN-γ secreting cells and cytokine-producing CD4+ T cells. Overall, our data demonstrate that homologous EZIKV + poly (I:C) prime-boost immunization is sufficient to induce more robust specific-EZIKV humoral and cellular immune responses than the other strategies that contemplate homologous DNA (pVAX-EZIKV) or heterologous (pVAX-EZIKV/EZIKV + poly (I:C), and vice-versa) immunizations.
引用
- Amaral MP, Apostolico JS, Tomita N, et al. Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses. Vaccine. 2020. PMID: 32247567. doi:10.1016/j.vaccine.2020.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。